Mediators of Inflammation

Mediators of Inflammation / 2016 / Article
Special Issue

Sphingolipids in Inflammation: From Bench to Bedside

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 3827684 |

Loubna Abdel Hadi, Clara Di Vito, Laura Riboni, "Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces", Mediators of Inflammation, vol. 2016, Article ID 3827684, 13 pages, 2016.

Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces

Academic Editor: Alex Kleinjan
Received13 Aug 2015
Revised27 Nov 2015
Accepted06 Dec 2015
Published05 Jan 2016


Complex sphingolipids are essential structural components of intestinal membranes, providing protection and integrity to the intestinal mucosa and regulating intestinal absorption processes. The role of sphingolipid signaling has been established in numerous cellular events, including intestinal cell survival, growth, differentiation, and apoptosis. A significant body of knowledge demonstrates that intestinal sphingolipids play a crucial role, as such and through their signaling pathways, in immunity and inflammatory disorders. In this review, we report on and discuss the current knowledge on the metabolism, signaling, and functional implications of sphingolipids in inflammatory bowel disease (IBD), focusing on the different aspects of sphingolipid actions on inflammatory responses and on the potential of sphingolipid-targeted molecules as anti-IBD therapeutic agents.

1. Introduction

Complex sphingolipids, including sphingomyelin (SM) and glycosphingolipids (GSLs), are essential components of intestinal membranes, providing protection and integrity to the mucosa and regulating intestinal digestion and absorption processes. As in other organs, in the intestine, simple sphingolipids/sphingoids, which are intermediates of sphingolipid metabolism, are involved in the control of key cellular events such as survival, proliferation, differentiation, and apoptosis. Indeed, the metabolism of complex sphingolipid includes enzymes involved in different signaling pathways, which lead to the formation of bioactive molecules, including ceramide (Cer) and sphingosine (Sph), as well as their 1-phosphorylated derivatives ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P).

The role and impact of sphingolipids and sphingolipid-mediated signaling emerged in their relevance in intestinal disorders, when aberrations in their metabolism lead to an altered sphingolipid homeostasis. Herein, we review our current knowledge on the impact of sphingolipid disequilibrium on intestinal inflammation, focusing on inflammatory bowel disease (IBD).

2. Inflammatory Bowel Disease

The term IBD encompasses a group of common chronic inflammatory disorders affecting the gastrointestinal tract [1]. The major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). Despite some overlapping clinical features, these diseases are characterized by distinct inflammatory profiles, gut microbiota composition, and symptomatology [2, 3]. CD potentially affects any portion of the alimentary tract and is characterized by a discontinuous and ulcerous transmural inflammation, associated with complications (e.g., intestinal granulomas, obstructions, abscesses, strictures, and fistulas) [3]. In UC, a continuous inflammation involves only the superficial layers of the intestinal mucosa and is localized to regions of the gut most highly colonized by bacteria, specifically at the rectum and moving proximally along the large bowel [4].

The pathogenesis of IBD is complex (Figure 1) and for many aspects remains unclear. The general hypothesis is that IBD develops as a result of a persistent alteration of intestinal homeostasis, leading to a perturbation of the balance between the intestinal mucosa and the gut microbiome [1]. Diverse factors, such as genetic, environmental, and immunologic variations, participate to and influence the onset and reactivation of this disease [4, 5]. There is compelling evidence that an inherited/acquired genetic predisposition that leads to barrier disruption and overreaction of the mucosal immune responses to enteric/environmental antigens are major factors contributing to the pathogenesis of IBD [68]. The dysregulated reaction of the mucosal immunity to normal intestinal microflora may be induced by defects in the epithelial barrier (increased intestinal permeability), adherence of bacteria, or expression of the “defensins” proteins.

The interaction among intestinal epithelial cells (IECs), intestinal microbes, and local immune cells plays a crucial role in the maintenance of the intestinal homeostasis and is disrupted in IBD, leading to overreaction of the mucosal immune response to normal intestinal microflora. Indeed, a common histopathological feature of IBD is an excessive immune activation, characterized by an exaggerated infiltration of mast cells, monocytes/macrophages, and polymorphonuclear leukocytes into the intestinal epithelium. This overabundance of immune cells is accompanied by continuous and dramatic production of proinflammatory stimuli, including cytokines, growth factors, and adhesion molecules, as well as of inflammatory mediators (especially those of the eicosanoid family) and reactive oxygen species (ROS) [9, 10]. All this results in the development of a severe and pervasive inflammation that promotes and exacerbates IBD.

3. Intestinal Sphingolipid Equilibrium

The small intestine is lined by a single layer of self-renewing IECs, which cover the surface of fingers-like projections called villi, and that of flask-like structures around the base of villi called crypts. The large intestine does not contain villi. Complex sphingolipids are present throughout the intestinal tract, with preferential localization in the apical membrane of polarized IECs, endowing its architecture with enhanced stability and digestive/absorptive capacity. Enterocytes of the small intestine are characterized by the selective abundance of SM and glucosylceramide (GlcCer), whose levels account for more than twofold that of the colonic mucosa and about 40% of total lipids [11]. The high content of sphingolipids in the small intestine is associated with selective enrichment and localization of several species in the apical membrane of the absorptive villous cells, which parallels the continuous process of mucosal cell differentiation throughout the crypt-villus axis [12]. Indeed, individual sphingolipids are differently distributed in villus and crypt cells, higher amounts of Sph, GlcCer, and GM3 being present in villi and Cer, trihexosyl-Cer, and GD3 ganglioside in crypts [13].

Sphingolipids have rapid turnover, and their levels are controlled by the balance between synthesis and degradation. As in most cells, the overall metabolism of intestinal sphingolipids is complex and intricate (Figure 2(a)) and involves multiple enzymes, also present in different isoforms and subcellular districts. Sphingolipids of the intestinal tract are synthesized via either “de novo pathway” (initiated by serine condensation with palmitoyl-CoA through serine palmitoyltransferase) or the “salvage pathway” (the recycling of free Sph derived from sphingolipid catabolism). In both pathways, the action of ceramide synthase (CerS) is required to produce Cer, and five of the six known isoforms of CerS are expressed in the intestinal mucosal cells [11]. The newly formed Cer in the endoplasmic reticulum is then transferred to the Golgi apparatus through either the protein (CERT) mediated transport (for SM biosynthesis) or a vesicle-mediated route (for both SM and GSLs formation) [14]. Two types of SM synthases (SMS) (SMS1 and SMS2) have been identified and cloned in the intestinal cells. SMS1 resides in the Golgi whereas SMS2 mainly presents at the plasma membrane. GlcCer synthase is highly expressed in the small and large intestine, rendering GlcCer the major intestinal GSL. GlcCer is also the substrate of galactosyltransferase and then of sialyltransferase abundant in villous cells, to provide lactosyl-Cer and GM3 [11].

Concerning sphingolipid catabolism, the intestine is characterized by the ability to hydrolyze both endogenous and exogenous (dietary-derived) sphingolipids. Intestinal SM degradation, catalyzed by sphingomyelinase (SMase) and ceramidase (CDase), has been the object of different studies. SMase and CDase can act both inside mucosal cells and as ectoenzymes, being present either in the intracellular environment or on the outer surface of the cell membrane or in the intestinal lumen. So far, three isoforms of SMase, acid (A-SMase), neutral (N-SMase), and alkaline (Alk-SMase), are figured out in the intestine with different compartmentalization. A-SMase (and in minor amounts N-SMase) is mainly localized in highly proliferating crypt cells, particularly of the proximal intestine, and appears to be mainly involved in the hydrolysis of SM internalized by endocytosis [11]. Alk-SMase is found preferentially in the middle part of the intestine, primarily at the brush border, and is recognized as the major enzyme for dietary SM digestion, even if it is also able to hydrolyze the plasma membrane SM of mucosal cells [15].

Besides SMase, also CDase is present in the intestine as three isoforms, including the neutral (N-CDase), the alkaline, and the acid one, the former exhibiting the highest catalytic activity in the presence of bile salts [16]. Although direct absorption of SM and Cer in humans cannot be excluded [17], there is ample evidence that free Sph, produced through Alk-SMase and N-CDase digestion, is the major absorbed product of dietary SM. Once internalized into the enterocytes, Sph is rapidly metabolized, mainly to S1P by sphingosine kinase (SphK). In the small intestine of mice, the total SphK activity was shown to be about twofold that of colon, and SphK1 contributed approximately 40% to the total kinase activity in small intestine, whereas it was the prevalent isoform in colon [18]. Interestingly, an unidentified SphK with high activity toward phytosphingosine was reported to be the prominent SphK in the small intestine [18]. S1P lyase that degrades S1P to phosphoethanolamine and palmitaldehyde is expressed at high levels in the intestinal mucosa [19], most probably to reduce the level of S1P (and Sph) derived from the digestion of dietary sphingolipids.

This intricate network of metabolic reactions leads to the physiological presence of multiple sphingolipid molecules, which play fundamental roles in the digestive, absorptive, protective, and defense properties of the intestine.

4. Aberrant Sphingolipid Metabolism Leads to a “Proinflammatory” Sphingolipid Pattern in IBD

There is compelling evidence that dysregulated production of several sphingolipid molecules occurs along with IBD and contributes as a major factor to the pathogenesis and maintenance of this disorder. Indeed, sphingolipid metabolism and the cellular level/distribution of different sphingolipids exhibit significant changes in IBD. These variations not only alter the healthy sphingolipid equilibrium essential for intestinal functions, but also implicate cell-signaling responses that precipitate the pathology.

Accumulating pieces of evidence demonstrate that a significant increase in some sphingolipid species, including SM, Cer, and the sphingoids mediators C1P and S1P, is associated with IBD and is counterbalanced by the decrease of other molecules, especially GlcCer and GM3 (Figure 2(b)). Indeed, SM and Cer are significantly increased in a colitis mouse model [20], as well as in feces of animals with dextran sulfate sodium- (DSS-) induced colitis (an experimental model of IBD) [21]. In agreement, and of relevance, high levels of SM and Cer were reported in the ileum from CD patients [22], providing evidence that SM and Cer generation accompanies and possibly aggravates chronic intestinal inflammation. Different enzymatic alterations appear to contribute to the increased SM in IBD. First, a decrease in Alk-SMase activity was demonstrated in human chronic colitis [23], possibly acting as a key mechanism to induce SM accumulation. In addition, colon samples from mice with a DSS-induced IBD exhibit downregulation of N-SMase, and, of relevance, concomitant upregulation of SMS2 [20].

Both the increase of glucocerebrosidase (responsible for GlcCer hydrolysis to Cer) and CerS activation were found in IBD and were suggested to be responsible for Cer elevation [24]. Moreover, in colon cancer cells, tumor necrosis factor α (TNF-α), a proinflammatory cytokine that plays a pivotal role in IBD, was shown to upregulate the de novo pathway of sphingolipid biosynthesis [25], and it is conceivable that this effect could contribute to Cer and SM accumulation in IBD. A further study on mice revealed that also Sph level is elevated in colon inflammation [26], most likely as a consequence of the increased expression and activity of N-CDase. Indeed, it was shown that N-CDase expression and activity increase in colon epithelium of mice during DSS-induced IBD [26]. On the contrary, it was shown that the ganglioside content of inflamed intestinal mucosa is significantly decreased [27]. Whether enhanced catabolism of gangliosides and/or decreased biosynthesis from Cer are responsible for ganglioside depletion in IBD remains unknown. In a rat model of intestinal inflammation, the 1-phosphorylated forms of Cer (C1P) and Sph (S1P) were shown to increase in a time-dependent fashion with inflammation [28]. The increase of S1P levels is of particular relevance in IBD colon and occurs not only in the intestine but also in blood, as a consequence of the enhanced expression of SphK1 [29]. On the contrary, the deficiency of SphK2 was shown to significantly reduce IBD severity [30].

It is unknown whether alterations of sphingolipid metabolism precede the onset of the chronic inflamed state of IBD, or the inflammatory condition induces them. It appears plausible that both conditions are operative, sphingolipid aberrations favoring and on their turn being favored by the IBD condition.

5. Sphingolipid Unbalance: A Multiarmed Force of IBD

IBD has many tiers of initiation, progression, and evolvement to reach the summit of intestinal damage. The multiple and significant alterations of sphingolipids and bioactive sphingoids level associated with IBD result in a variety of effects on these tightly interrelated tiers, including the epithelial barrier integrity, immune cell targeting and signaling, and innate/adaptive immune responses (Figure 3).

5.1. Sphingolipid Alterations Favor the Disruption of the Intestinal Barrier in IBD

A critical function of the intestinal epithelium is to form a selective permeable barrier that allows the appropriate absorption of nutrients but limits the permeation of noxious agents, such as pathogens, toxins, and antigens, from the luminal environment [31]. This specialized permeable barrier is achieved by different structures, including mucus and intercellular tight junctions (TJs), which control luminal molecules-intestinal cells interactions and paracellular permeability [32]. It is recognized that the disruption of the intestinal TJ barrier, followed by the permeation of luminal noxious agents, and perturbation of the mucosal immune system and inflammation, acts as a key trigger of IBD development [33]. IBD patients exhibit increased intestinal permeability, which favors bacterial/viral infections and thus onset/relapse of IBD. Observations on IBD patients pointed out the role of bacteria in this inflammation, and antibiotics were found to be effective in some patients with IBD [34]. In agreement, most mouse models of colitis require intestinal bacteria to occur [35].

It is noteworthy that the intestinal permeability is also influenced by the content and pattern of IEC sphingolipids (Figure 3). Both Sph and its N-acylated derivative Cer are elevated in IBD and emerged as antibarrier effectors (Figure 3(a)). By using fumonisin B1 (a fungal inhibitor of CerS that leads to Sph accumulation and depletion of complex sphingolipids), it was found that the toxin induces a primary defect in barrier function, increasing intestinal epithelial permeability [36]. In addition, fumonisin B1 treatment in pigs resulted in a significant increase of intestinal colonization by pathogenic E. coli [37]. As far as Cer is concerned, it is recognized that it selectively accumulates in cholesterol- and sphingolipid-enriched membrane microdomains, which also include TJs [33]. The packing of Cer in these microdomains alters the lipid rafts composition, contributing to a disturbed barrier function [38]. In agreement, the neutralization of cell surface Cer prevented the loss of barrier function induced by platelet-activating factor (PAF) [38].

Opposite to the negative effects of Sph and Cer at the intestinal barrier, GSLs (gangliosides and GlcCer), enriched on the luminal membrane of enterocytes, protect intestinal mucosa from injuries induced by bile salts, gastric juice acidity, and toxins/pathogens entry (Figure 3(b)). In particular, through their negative charge, gangliosides such as GM1 and GM3 are able to bind, and then inactivate, the toxins of Vibrio cholerae, E. coli, and Shigella [3941]. Of interest, these antibacterial effects can be improved by dietary gangliosides. A recent in vivo study on lipopolysaccharide- (LPS-) induced inflammation revealed that dietary gangliosides inhibit the degradation of gut occludin, a major protein of intestinal TJs [42], implicating them in the intestinal barrier properties. In addition, dietary GlcCer was shown to induce the expression of claudin-1, thus improving TJ properties [43].

Overall, it emerges that the significant reduction of GSLs, especially GM3 and GlcCer, associated with the concomitant elevation of Sph and Cer, markedly concurs to alter the permeability properties of the intestinal epithelium in IBD.

5.2. Sphingolipids and Cytokine Networks in IBD

A well-recognized feature of IBD is the overproduction of proinflammatory cytokines, mainly represented by TNF-α, interleukin- (IL-) 6, and IFN-γ [44]. In the IBD intestine, excess of macrophages and subpopulations of macrophages not normally present in the lamina propria of the intestine is present, indicating ongoing recruitment to the inflamed bowel. The abundance and activation of these innate and adaptive immune cells in the intestinal mucosa result in increased local levels of proinflammatory mediators [44]. In active IBD, an elevated expression of TNF-α occurs, consequent to the high density of TNF-α producing cells, especially macrophages within the lamina propria [45]. The high level of TNF-α contributes to the inflammatory tissue damage, by impairing the integrity of epithelial and endothelial membranes and increasing the recruitment of inflammatory cells [46].

Different studies implicate a strong network connection between cytokines and different sphingolipids as critical in the regulation of inflammatory pathways and immune reactions in IBD. In this connection, SphK1 emerged as key actor, being activated by several cytokines, among which TNF-α plays a prominent role [47]. SphK1 acts as important mediator of various cellular processes in IBD, most likely downstream of TNF-α and upstream of cyclooxygenase- (COX-) 2. Indeed, in a DSS-induced colitis model, Snider et al. [29] reported that SphK1 depletion failed to induce colonic COX-2 and the consequent prostaglandin (PG)E2 production, which contributes to the exacerbation of the inflammatory colon damage. In the same study, it was reported that S1P produced by SphK1 is able to promote neutrophil infiltration into the crypts and lamina propria of the colon [29]. Thus, S1P emerged as a chemoattractant for granulocytes in the inflamed intestine either directly or through the production of other local chemoattractants, and in both cases the SphK1/S1P pathway promoted the tissue inflammatory reaction. In a follow-up study, the same group provided further insights into the distinct roles of hematopoietic (bone marrow-derived) and extrahematopoietic (intestinal) SphK1/S1P pathway in the pathogenesis of IBD [48]. Hematopoietic-derived SphK1 was found as major contributor to circulating S1P, which, on its turn, was implicated in lymphocyte egress from the spleen, and circulating neutrophil increase [48]. This led to a high neutrophil/lymphocyte ratio, a steady indicator of systemic inflammation in colitis [49]. In addition, both hematopoietic and extrahematopoietic S1P were involved in the increased expression of IL-1β and IL-6, as well as in the phosphorylation of STAT3, a tightly regulated transcription factor implicated in chronic colitis associated cancer [48, 50]. As far as the extrahematopoietic SphK1/S1P is concerned, this was shown to be essential for the autocrine induction of COX-2 in the colon tissue [48].

Although the absence of SphK1 was protective against DSS-induced colitis [51], SphK2 depletion resulted in enhanced proliferation and proinflammatory cytokine production, and thus IBD progression [30, 51]. Indeed, knockout mice for SphK2 were shown to develop more severely damaged and necrotic colonic mucosa, with pronounced loss of crypt structures and extensive infiltration of inflammatory cells, eosinophils, and neutrophils [30]. In SphK2(−/−) mice, mesenteric lymph node cells overproduced proautoimmunity cytokines, and T-cells induced more rapid and robust IBD in scid recipients which enhanced the pathological phenotypes of colitis severity, suggesting that SphK2 negatively modulates inflammatory responses and significantly reduces IBD severity [30]. These findings support the hypothesis that therapeutic enhancement of SphK2 activity and/or depletion of SphK1 may be effective treatments for the exuberating inflammation of IBD.

Different reports demonstrate that Cer generated by SMase is able to exert powerful effects, even opposite, on IBD cytokine production and signaling. In the inflammatory processes of the gastrointestinal tract, the infiltration of inflammatory cells into the intestinal mucosa leads to a marked increase of IL-1β and then to NF-κB activation [44]. Both IL-1β and NF-κB exert detrimental effects, by inducing the expression of proinflammatory mediators that orchestrate and sustain the inflammatory response, finally determining tissue damage. A study by Homaidan et al. [52] on murine IECs demonstrated that IL-1β activates N-SMase through NF-κB, thus inducing significant accumulation of Cer. Cer was found to mimic IL-1β in enhancing PGE2 generation through COX-2 induction and by promoting the rise of chloride and water secretion, a typical alteration of IBD patients [52, 53]. Cer generated by N-SMase was shown to induce apoptosis in human colon HT-29 cells, through NF-κB activation and IL-8 expression [54]. In addition, also the A-SMase-derived Cer was apoptotic, but by activating NF-κB on distinct κB complexes [54]. Besides IL-1β and TNF-α, also LPS induces the release of inflammatory cytokines from monocyte/macrophages via A-SMase activation, and Cer generation leads to the expression of a variety of genes and results in inflammatory responses [55].

It is recognized that Cer can exert opposite effects depending on its enzymatic origin and/or site of production [56]. Indeed, opposite to the proinflammatory effects of Cer produced by N- and A-SMase in the intestine, Cer generated by Alk-SMase was shown to promote intestinal anti-inflammatory pathways. In fact, the conversion of the apical membrane SM to Cer by intestinal Alk-SMase was found to inhibit cholera toxin endocytosis and host cells intoxication [57]. Further support for the anti-inflammatory action of intestinal Alk-SMase was provided by a report showing that, in rats with DSS-induced colitis, the intrarectal instillation of Alk-SMase induced TNF-α inhibition, significantly reduced the inflammation score, and protected the colonic epithelium from inflammatory destruction [58]. These studies, together with the finding that Alk-SMase is downregulated in IBD [23], support the notion that the decrease of this anti-inflammatory enzyme may be of relevance in IBD pathogenesis and progression.

The excessive cytokine production in IBD appears to be favored also by the decrease of gangliosides occurring in this disease. It is recognized that gangliosides in the apical intestinal surface can influence numerous processes, including microbial attachment, toxin production, and infectivity of several intestinal pathogens (Figure 3(b)), and increased ganglioside catabolism occurs in IBD and results in increased proinflammatory signaling [59]. Intriguingly, dietary gangliosides emerged as effective elements in reducing proinflammatory mediators of IBD. Indeed, an induced ganglioside increase was shown to inhibit both TNF-α and IL-1β proinflammatory signals in rats [27]. Moreover, in a cultured infant bowel exposed to LPS in hypoxic conditions, gangliosides were able to reduce both IL-6 and IL-8 production [60].

5.3. Cross-Communication of Sphingolipid Messengers with Eicosanoid and Glycerolipid Signaling

Aberrant production of bioactive lipids of the eicosanoid family, especially PGs, was identified to drive chronic inflammation by dysregulating signaling pathways and/or cellular events and leading to abnormal immune functions [61]. Eicosanoids, including PGs, are generated from arachidonic acid, released from cell membrane phospholipids mainly by phospholipase-A2 (PLA2). Arachidonic acid is then converted to PGs via the COX pathway. Of the two known COX isoforms (COX-1 and COX-2), it is COX-2 that is induced during acute or chronic inflammation [62].

Increased PG production occurs within the gastrointestinal mucosa of patients with IBD, and in experimental models of IBD [63]. As a consequence, PGs and especially PGE2 act as proinflammatory factors and tool in IBD. Different studies progressively revealed a key role of sphingolipids in the modulation of eicosanoid production in inflammatory processes [64] (Figure 3(a)). Initial studies showed that Cer and Sph were able to induce PGE2 production [65]. Cer was shown to enhance cytosolic PLA2 (cPLA2) activity and PG formation through direct binding to the enzyme [66]. Subsequent studies demonstrated that both C1P and S1P are involved in the regulation of PGE2 production [6769], by acting through different mechanisms. C1P was shown to activate cPLA2 either directly or by promoting its translocation to intracellular membranes [7072]. After binding to different subtypes of its receptors, S1P acts downstream of Cer, by causing strong and prolonged expression of COX-2 [73], through inducing transcription and mRNA stabilization [74, 75].

The proinflammatory cytokines IL-1β and TNF-α were shown to regulate both cPLA2α and COX-2 to promote SM metabolism and to produce C1P and S1P formation [76]. This signaling pathway starts with A-SMase activation, which results in the reduction of the SM-mediated inhibition of cPLA2α. Moreover, the two cytokines activate SphK1 and ceramide kinase 1, the Cer pool generated by A-SMase finally promoting both C1P and S1P biosynthesis. In response to proinflammatory cytokines, C1P and S1P exhibit a significant synergistic effect on the activation of cPLA2α and COX-2, and thus on the production of the key inflammatory mediators PGE2 [67].

Further support to IBD maintenance derives from the different catalytic activities exhibited by the Alk-SMase. This enzyme is able to hydrolyze not only SM, but also other choline phospholipids, including lysophosphatidylcholine, with reduction of lysophosphatidic acid, and PAF [15, 77]. Thus, the Alk-SMase reduction of IBD appears to be functional to signaling alterations that potentiate IBD, by reducing the anti-inflammatory actions exerted by SM and PAF and by promoting the proinflammatory lysophosphatidic acid.

Although much remains to be understood about these multiple signaling interactions, the actual knowledge linking sphingolipids with eicosanoids and glycerolipid messengers provides a new conceptual view on how alterations of sphingolipid signaling in IBD act not only as such but also through regulation of other signaling molecules. This leads to increased efficacy in promoting and maintaining the chronic state of IBD.

6. Sphingolipids: Potential Therapeutic Benefits/Targets in IBD

The global incidence of IBD is increasing with time [78]. Actually, a step-up strategy is used in the management of IBD, therapeutic treatments including 5-aminosalicylic acid, glucocorticoids, immunomodulators, and anti-TNF agents [79]. Despite advancements in therapy with the introduction of anti-TNF agents [80, 81], IBD gradually causes serious effects in terms of morbidity, work disability, and quality of life [82]. The finding that multiple sphingolipid alterations are associated with IBD has prompted investigations on the targeting of sphingolipids as a potential field of therapy for managing progression and morbidity of this disease.

6.1. Dietary Bioactive Sphingolipids: A Gift from Nourishment

It is generally accepted that dietary components are involved in immune regulation. The intestinal immune system, especially, seems to be directly affected by the digestion and absorption of dietary compounds and, among them, dietary lipids have emerged as major determinants of the intestinal immune responses, mainly after conversion into lipid mediators [83]. Indeed, as described above, sphingolipid metabolites act as multifaceted bioactive molecules in IBD, and different studies demonstrated that dietary complex sphingolipids, including gangliosides and SM, possess the potential of effective compounds.

Initial studies on dietary gangliosides demonstrated that the sialylated GSLs of human milk exert beneficial effects in infant bowel infections, through enterotoxin-inhibiting activity and maintenance of the intestinal barrier integrity [84]. Thereafter, it was shown that milk gangliosides were able to inhibit adhesion and suppress the growth of E. coli. In particular, an infant formula, specifically enriched with GD3 and GM1 gangliosides, lowered E. coli content and concomitantly increased that of bifidobacteria, suggesting a ganglioside role in the development of intestinal immunity [85]. Furthermore, Schnabl et al. [60] demonstrated that ganglioside preexposure to LPS treatment reduces bowel necrosis and endothelin-1 production in response to LPS, by suppressing infant bowel production of different proinflammatory mediators, such as nitric oxide, leukotriene B4, PGE2, hydrogen peroxide, IL-1β, IL-6, and IL-8. Moreover, very recently, it was reported that gangliosides, especially GD3, ameliorate intestinal injury not only by suppressing proinflammatory mediators, but also by upregulating anti-inflammatory molecules, such as chemokines and the cytokine IL-10 [86] (Figure 3(b)).

Besides gangliosides, also dietary SM was shown to exert biomodulatory activities in intestinal inflammation, though with contrasting results. In the mouse colon, it was observed that the simultaneous administration of SM and DSS prevents the increase of myeloperoxidase (MPO) activity, a marker of neutrophil influx into the inflamed colon [87]. Moreover, Mazzei et al. [88] recently reported that dietary SM decreased colonic inflammatory lesions and disease progression in mice with DSS-induced colitis. On the contrary, two recent papers by Hausmann’s group showed that, after metabolism to Cer, dietary SM triggers apoptosis in murine IECs and aggravates intestinal inflammation in acute DSS-induced colitis and in IL-10 knockout mice [21, 89]. The reasons of these opposite findings on dietary SM in intestinal inflammation remain to be clarified. Although it cannot be excluded that the use of different mouse strains may be responsible for the anti- and proinflammatory effects of dietary SM, it appears likely that the different composition and intestinal hydrolysis of the administered SM (of milk and egg origin, resp.) play a major role.

Taken together, these findings suggest that the dietary assumption of specific types of complex sphingolipids might be beneficial as preventive/therapeutic strategy against IBD.

6.2. Regulation of Sphingolipid Metabolites by Dietary Materials

In addition to dietary sphingolipids, the assumption of dietary compounds able to modify the intestinal sphingolipid metabolism has emerged as an intriguing possibility to influence the IBD status.

It has been demonstrated that a diet enriched with fibers and fats is able to influence the expression of both intestinal SMases and CDases. Psyllium, a water soluble fiber partly digested by bacterial flora, increased the activity of Alk-SMase and decreased that of A-SMase and N-CDase alleviating inflammation, whereas a high-fat diet exerted opposite effects [90]. Moreover, in IL-10 KO mice with colitis, it was demonstrated that the VSL#3 probiotic upregulates Alk-SMase activity, suggesting its potential as anti-inflammatory agent [91].

Luteolin, a tetrahydroxyflavone present in a variety of vegetables, fruits, and medicinal herbs, has been shown to function as an antioxidant, anti-inflammatory, and anticancer agent [92]. Very recently, we reported that dietary luteolin is able to unbalance the sphingolipid rheostat by inhibiting both S1P biosynthesis and Cer traffic in colon cancer cells [93], suggesting its dietary introduction/supplementation as a potential strategy to improve inflammation in colorectal cancer. These findings prompt further investigations on dietary molecules able to modulate sphingolipid metabolism as anti-IBD foods.

6.3. Targeting Sphingolipids: A Potential Anti-IBD Strategy

The discovery of alterations of sphingolipid metabolism and signaling in IBD paved the way for the discovery of pharmacological approaches to prevent/treat this disease. Up to now, several compounds have been discovered to manipulate the SM cycle and S1P metabolism/receptors, and these were evaluated for their potential therapeutic benefit generally in inflammation, and especially in IBD.

So far, the most high-profile drug that improves inflammation via S1P receptor (S1PR) modulation and is assessed in vivo is the fungal metabolite fingolimod (FTY720). Differently from typical immunosuppressive drugs, its mode of action is not via inhibition of T-cell function, but via downregulation of S1P1 on lymphocytes, leading to the inhibition of their egress from the lymph nodes [94]. As a consequence, FTY720 reduces the number of T-cells circulating between lymph nodes and the peripheral site of tissue inflammation. In agreement with this action, Mizushima et al. [95] demonstrated the efficacy of FTY720 in decreasing the severity of spontaneous colitis in the IL-10-deficient mouse model. FTY720 induced accelerated homing and sequestration of T-cells into Peyer’s patches and mesenteric lymph nodes, resulting in a reduction of CD4+ T lymphocytes into the lamina propria [95]. An additional study provided new evidence on the immunosuppressive properties of FTY720. In particular, in a chemically induced mouse model of colitis, FTY720 treatment markedly reduced the severity of intestinal inflammation [96]. This therapeutic effect of FTY720 was associated with downregulation of different proinflammatory cytokines, paralleled by a functional activity of CD4+CD25+ regulatory T-cells and prominent upregulation of anti-inflammatory mediators [96].

The finding that S1P1 modulation was the major mechanism of FTY720’s efficacy prompted the search for second-generation compounds, with high selectivity to S1P1, and lower clinical adverse events (linked to its agonistic activity to S1P3), such as symptomatic bradycardia [97]. Among new drugs, KRP-203, S1P1/4/5 agonist prodrug with a molecular structure resembling FTY720 with high selectivity to S1P1, was developed for immunomodulation in autoimmune diseases and organ transplantation [98]. In the IL-10-deficient mouse, a validated model of human IBD, KRP-203 regulated not only T-cell response but also B-cell one [99]. Its treatment resulted in a significant reduction in the severity of colitis and in the number of CD4(+) T-cell and B220(+) B-cell subpopulations and T-helper 1 (Th1) cytokine production in colonic mucosa, a histopathological hallmark of IBD [99]. Thus, the use of KRP-203 emerged as an option to be tapped into effective immunointervention in IBD.

W-061, a novel and potent S1P1 agonist, structurally different from Sph and active in vivo without undergoing phosphorylation, showed effectiveness for alleviating multiple aspects of chronic intestinal inflammation in DSS-induced colitis, such as preventing mucosal thickness and mucin depletion induced by DSS. The novel effect attributed exclusively to W-0671 as S1PR agonist is the suppression of Th17 and Th1 increase in the lamina propria, by the sequestration of these cells into secondary lymphoid tissues [100]. It has been recently demonstrated that SEW 2871, another selective S1P1 agonist, ameliorates colitis in IL-10-deficient mice, by reducing proinflammatory cytokines production and promoting the expression of TJ typical proteins [101]. A further, highly specific S1P1 agonist, named RPC 1063, has been successfully tested in animal models of IBD and is currently being used as an oral therapeutic in phase II clinical trials of UC [102].

Besides S1PR antagonists, other drugs exhibiting a promising therapeutic benefit in IBD are those targeting the S1P axis and acting as SphK inhibitors. Different studies demonstrated that the orally available inhibitors of SphKs, ABC747080 and ABC294640, are effective in inhibiting the severity of colitis [29, 103, 104]. This protection is likely due to the significant decrease, induced by the inhibitors, of a broad spectrum of inflammatory mediators, such as TNF-α, COX-2, IL-1β, IFN-γ, MPO, and IL-6, including S1P. Moreover, SphK inhibitors were able to attenuate the effects of TNF-α-induced increase in the expression of the adhesion proteins physiologically involved in leukocyte recruitment.

Of notice, in both acute and chronic models of UC, it has been reported that SphK inhibitors and Dipentum, an FDA-approved anticolitis drug, exhibit similar effects in reducing inflammation extent and severity, with the best results in a combinatory delivery [103]. These results are encouraging and shed light on a possible combination of SphK inhibitors and anti-IBD drugs for further clinical IBD improvement. Overall, it emerged that SphK is an excellent target for the development of new anti-IBD drugs.

Additional studies investigated the SM cycle as therapeutic target in IBD. By using SMA-7, an inhibitor of A-SMase and N-SMase, it was found that, besides suppressing Cer production, it was effective in inhibiting NF-κB activation and inflammatory cytokine release from macrophages [55]. In murine models of colitis, the oral administration of SMA-7 induced a significant decrease in the NF-κB-dependent cytokine levels and reduced alterations and damage in the colonic mucosal layer [55]. Whether N- and A-SMases play a different role in the regulation the IBD inflammation and the contribution of Cer inhibition and/or S1P reduction as key effectors of the SMA-7 effect remain to be clarified.

Finally, also glycosylated sphingolipids recently emerged as compounds of potential benefit in IBD. In particular, cerebroside D, a glycoceramide compound from fungal culture, was presented for its immunosuppressive activity and efficiency in improving DSS-induced colitis in mice [105]. Its anti-inflammatory mechanism involves multiple effects against activated T-cells in colon, such as regulation of the cytokine profile and apoptosis induction in activated T-cell effectors. Thus, by interfering with naïve T-cell activation, cerebroside D appears to be of relevance for IBD management.

7. Closing Remarks

Taken together, a huge and increasing volume of experimental evidence points to the importance of sphingolipids/sphingoids molecules, and their enzymes, in IBD development and fate. However, at present, several gaps in our knowledge and many questions need to be understood better. Among them, more knowledge is required on the mechanisms underlying the in vivo digestion/absorption of sphingolipids in the gastrointestinal system, as well as on the effective concentrations shifting them from food components to dietary bioactive nutrients. The influence of specific lipids, and their modifying enzymes, on intestinal lipid-barrier control is an area of great promise that needs to be investigated further to develop novel treatment strategies that strengthen the intestinal barrier and possibly halt, or at least slow down, the initial alterations leading to IBD. It will be also of relevance to better understand the multifaceted role of sphingolipid molecules in IBD and their subcellular localization, as well as cross talk with other intestinal factors involved in this disease. The potential of diet components in changing the sphingolipid amount and pattern in the gut remains an open question. In the “future food” field, it is a hard challenge to find out new compounds targeting sphingolipid metabolism and able to self-actualize, or to combine with other drugs, for effective IBD treatment with minimal side effects. Based on the preclinical findings of the anti-IBD potential of sphingolipid, hard work remains to establish their efficacy and to upgrade and improve treatments to clinical endpoints. Deeper understanding of the proper role of sphingolipids and their enzymes in controlling the intestinal properties and in promoting the pathogenesis and progression of IBD will generate new perspectives in the development of “sphingolipid-centered” therapeutic strategies that control the onset and perpetuation of this disabling inflammation.


IBD:Inflammatory bowel disease
CD:Crohn’s disease
UC:Ulcerative colitis
IECs:Intestinal epithelial cells
ROS:Reactive oxygen species
CerS:Ceramide synthase
SMS:SM synthases
Alk-SMase:Alkaline sphingomyelinase
N-SMase:Neutral sphingomyelinase
A-SMase:Acid sphingomyelinase
N-CDase:Neutral ceramidase
SphK:Sphingosine kinase
DSS:Dextran sulfate sodium
TNF-α:Tumor necrosis factor alpha
TJ:Tight junction
PAF:Platelet-activating factor
NF-κB:Nuclear factor kappa B
cPLA2:Cytosolic phospholipase-A2α
S1PR:S1P receptor.

Conflict of Interests

The authors declare that no financial conflict of interests exists.


  1. K. J. Maloy and F. Powrie, “Intestinal homeostasis and its breakdown in inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 298–306, 2011. View at: Publisher Site | Google Scholar
  2. M. W. Laass, D. Roggenbuck, and K. Conrad, “Diagnosis and classification of Crohn's disease,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 467–471, 2014. View at: Publisher Site | Google Scholar
  3. K. Conrad, D. Roggenbuck, and M. W. Laass, “Diagnosis and classification of ulcerative colitis,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 463–466, 2014. View at: Publisher Site | Google Scholar
  4. A. Kaser, S. Zeissig, and R. S. Blumberg, “Inflammatory bowel disease,” Annual Review of Immunology, vol. 28, pp. 573–621, 2010. View at: Publisher Site | Google Scholar
  5. B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011. View at: Publisher Site | Google Scholar
  6. T. Kucharzik, C. Maaser, A. Lügering et al., “Recent understanding of IBD pathogenesis: implications for future therapies,” Inflammatory Bowel Diseases, vol. 12, no. 11, pp. 1068–1082, 2006. View at: Publisher Site | Google Scholar
  7. M. C. Dubinsky, K. Taylor, S. R. Targan, and J. I. Rotter, “Immunogenetic phenotypes in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3645–3650, 2006. View at: Google Scholar
  8. N. Gassler, C. Rohr, A. Schneider et al., “Inflammatory bowel disease is associated with changes of enterocytic junctions,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 281, no. 1, pp. G216–G228, 2001. View at: Google Scholar
  9. L. Kruidenier, I. Kuiper, C. B. H. W. Lamers, and H. W. Verspaget, “Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants,” Journal of Pathology, vol. 201, no. 1, pp. 28–36, 2003. View at: Publisher Site | Google Scholar
  10. U. Mahadevan, E. V. Loftus Jr., W. J. Tremaine, and W. J. Sandborn, “Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease,” American Journal of Gastroenterology, vol. 97, no. 4, pp. 910–914, 2002. View at: Publisher Site | Google Scholar
  11. R.-D. Duan and Å. Nilsson, “Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development,” Progress in Lipid Research, vol. 48, no. 1, pp. 62–72, 2009. View at: Publisher Site | Google Scholar
  12. E. M. Danielsen and G. H. Hansen, “Lipid raft organization and function in brush borders of epithelial cells,” Molecular Membrane Biology, vol. 23, no. 1, pp. 71–79, 2006. View at: Publisher Site | Google Scholar
  13. J.-F. Bouhours and R. M. Glickman, “Rat intestinal glycolipids. II. Distribution and biosynthesis of glycolipids and ceramide in villus and crypt cells,” Biochimica et Biophysica Acta, vol. 441, no. 1, pp. 123–133, 1976. View at: Publisher Site | Google Scholar
  14. L. Riboni, P. Giussani, and P. Viani, “Sphingolipid transport,” Advances in Experimental Medicine and Biology, vol. 688, pp. 24–45, 2010. View at: Publisher Site | Google Scholar
  15. R.-D. Duan, T. Bergman, N. Xu et al., “Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 38528–38536, 2003. View at: Publisher Site | Google Scholar
  16. M. Kono, J. L. Dreier, J. M. Ellis et al., “Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids,” The Journal of Biological Chemistry, vol. 281, no. 11, pp. 7324–7331, 2006. View at: Publisher Site | Google Scholar
  17. L. Ohlsson, E. Hertervig, B. A. G. Jönsson et al., “Sphingolipids in human ileostomy content after meals containing milk sphingomyelin,” The American Journal of Clinical Nutrition, vol. 91, no. 3, pp. 672–678, 2010. View at: Publisher Site | Google Scholar
  18. Y. Fukuda, A. Kihara, and Y. Igarashi, “Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1,” Biochemical and Biophysical Research Communications, vol. 309, no. 1, pp. 155–160, 2003. View at: Publisher Site | Google Scholar
  19. P. P. Van Veldhoven, “Sphingosine-1-phosphate lyase,” Methods in Enzymology, vol. 311, pp. 244–254, 1999. View at: Publisher Site | Google Scholar
  20. Y. Qi, C. Jiang, N. Tanaka et al., “PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 307, no. 5, pp. G564–G573, 2014. View at: Publisher Site | Google Scholar
  21. A. Fischbeck, K. Leucht, I. Frey-Wagner et al., “Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis,” Gut, vol. 60, no. 1, pp. 55–65, 2011. View at: Publisher Site | Google Scholar
  22. A. Braun, I. Treede, D. Gotthardt et al., “Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis,” Inflammatory Bowel Diseases, vol. 15, no. 11, pp. 1705–1720, 2009. View at: Publisher Site | Google Scholar
  23. U. Sjöqvist, E. Hertervig, Å. Nilsson et al., “Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity,” Inflammatory Bowel Diseases, vol. 8, no. 4, pp. 258–263, 2002. View at: Publisher Site | Google Scholar
  24. M. Scharl, K. Leucht, I. Frey-Wagner et al., “Knock-out of β-glucosidase 2 has no influence on dextran sulfate sodium-induced colitis,” Digestion, vol. 84, no. 2, pp. 156–167, 2011. View at: Publisher Site | Google Scholar
  25. S. G. E. Meyer and H. de Groot, “Cycloserine and threo-dihydrosphingosine inhibit TNF-α-induced cytotoxicity: evidence for the importance of de novo ceramide synthesis in TNF-α signaling,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1643, no. 1–3, pp. 1–4, 2003. View at: Publisher Site | Google Scholar
  26. A. J. Snider, B. X. Wu, R. W. Jenkins et al., “Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease,” Prostaglandins and Other Lipid Mediators, vol. 99, no. 3-4, pp. 124–130, 2012. View at: Publisher Site | Google Scholar
  27. E. J. Park, M. Suh, B. Thomson et al., “Dietary ganglioside inhibits acute inflammatory signals in intestinal mucosa and blood induced by systemic inflammation of Escherichia coli lipopolysaccharide,” Shock, vol. 28, no. 1, pp. 112–117, 2007. View at: Publisher Site | Google Scholar
  28. M. Dragusin, S. Wehner, S. Kelly et al., “Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus,” The FASEB Journal, vol. 20, no. 11, pp. 1930–1932, 2006. View at: Publisher Site | Google Scholar
  29. A. J. Snider, T. Kawamori, S. G. Bradshaw et al., “A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis,” The FASEB Journal, vol. 23, no. 1, pp. 143–152, 2009. View at: Publisher Site | Google Scholar
  30. E. T. Samy, C. A. Meyer, P. Caplazi et al., “Cutting edge: modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate,” Journal of Immunology, vol. 179, no. 9, pp. 5644–5648, 2007. View at: Publisher Site | Google Scholar
  31. J. R. Turner, “Intestinal mucosal barrier function in health and disease,” Nature Reviews Immunology, vol. 9, no. 11, pp. 799–809, 2009. View at: Publisher Site | Google Scholar
  32. T. Suzuki, “Regulation of intestinal epithelial permeability by tight junctions,” Cellular and Molecular Life Sciences, vol. 70, no. 4, pp. 631–659, 2013. View at: Publisher Site | Google Scholar
  33. S. H. Lee, “Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases,” Intestinal Research, vol. 13, no. 1, pp. 11–18, 2015. View at: Publisher Site | Google Scholar
  34. D. H. Kerman and A. R. Deshpande, “Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management,” Postgraduate Medicine, vol. 126, no. 4, pp. 7–19, 2014. View at: Publisher Site | Google Scholar
  35. C. O. Elson, Y. Cong, V. J. McCracken, R. A. Dimmitt, R. G. Lorenz, and C. T. Weaver, “Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota,” Immunological Reviews, vol. 206, pp. 260–276, 2005. View at: Publisher Site | Google Scholar
  36. E. N. Enongene, R. P. Sharma, N. Bhandari, K. A. Voss, and R. T. Riley, “Disruption of sphingolipid metabolism in small intestines, liver and kidney of mice dosed subcutaneously with fumonisin B1,” Food and Chemical Toxicology, vol. 38, no. 9, pp. 793–799, 2000. View at: Publisher Site | Google Scholar
  37. S. Bouhet, E. Le Dorze, S. Peres, J. M. Fairbrother, and I. P. Oswald, “Mycotoxin fumonisin B1 selectively down-regulates the basal IL-8 expression in pig intestine: in vivo and in vitro studies,” Food and Chemical Toxicology, vol. 44, no. 10, pp. 1768–1773, 2006. View at: Publisher Site | Google Scholar
  38. J. Bock, G. Liebisch, J. Schweimer, G. Schmitz, and G. Rogler, “Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function,” World Journal of Gastroenterology, vol. 13, no. 39, pp. 5217–5225, 2007. View at: Publisher Site | Google Scholar
  39. J. Holmgren, I. Lonnroth, J. E. Mansson, and L. Svennerholm, “Interaction of cholera toxin and membrane Gm1 ganglioside of small intestine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 7, pp. 2520–2524, 1975. View at: Publisher Site | Google Scholar
  40. B. Lanne, L. Uggla, G. Stenhagen, and K.-A. Karlsson, “Enhanced binding of enterotoxigenic escherichia coli K99 to amide derivatives of the receptor ganglioside NeuGc-GM3,” Biochemistry, vol. 34, no. 6, pp. 1845–1850, 1995. View at: Publisher Site | Google Scholar
  41. F. Lafont, G. T. van Nhieu, K. Hanada, P. Sansonetti, and F. G. van der Goot, “Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction,” The EMBO Journal, vol. 21, no. 17, pp. 4449–4457, 2002. View at: Publisher Site | Google Scholar
  42. E. J. Park, A. B. R. Thomson, and M. T. Clandinin, “Protection of intestinal occludin tight junction protein by dietary gangliosides in lipopolysaccharide-induced acute inflammation,” Journal of Pediatric Gastroenterology and Nutrition, vol. 50, no. 3, pp. 321–328, 2010. View at: Publisher Site | Google Scholar
  43. C. Kawada, T. Hasegawa, M. Watanabe, and Y. Nomura, “Dietary glucosylceramide enhances tight junction function in skin epidermis via induction of claudin-1,” Bioscience, Biotechnology, and Biochemistry, vol. 77, no. 4, pp. 867–869, 2013. View at: Publisher Site | Google Scholar
  44. C. Abraham and J. H. Cho, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2066–2078, 2009. View at: Publisher Site | Google Scholar
  45. E. J. Breese, C. A. Michie, S. W. Nicholls et al., “Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease,” Gastroenterology, vol. 106, no. 6, pp. 1455–1466, 1994. View at: Google Scholar
  46. S. H. Murch, C. P. Braegger, J. A. Walker-Smith, and T. T. MacDonald, “Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease,” Gut, vol. 34, no. 12, pp. 1705–1709, 1993. View at: Publisher Site | Google Scholar
  47. C. De Palma, E. Meacci, C. Perrotta, P. Bruni, and E. Clementi, “Endothelial nitric oxide synthase activation by tumor necrosis factor α through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 99–105, 2006. View at: Publisher Site | Google Scholar
  48. A. J. Snider, W. H. Ali, J. A. Sticca et al., “Distinct roles for hematopoietic and extra-hematopoietic sphingosine kinase-1 in inflammatory bowel disease,” PLoS ONE, vol. 9, no. 12, Article ID e113998, 2014. View at: Publisher Site | Google Scholar
  49. M. Celikbilek, S. Dogan, O. Ozbakir et al., “Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis,” Journal of Clinical Laboratory Analysis, vol. 27, no. 1, pp. 72–76, 2013. View at: Publisher Site | Google Scholar
  50. E. Degagné, A. Pandurangan, P. Bandhuvula et al., “Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs,” The Journal of Clinical Investigation, vol. 124, no. 12, pp. 5368–5384, 2014. View at: Publisher Site | Google Scholar
  51. J. Liang, M. Nagahashi, E. Y. Kim et al., “Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer,” Cancer Cell, vol. 23, no. 1, pp. 107–120, 2013. View at: Publisher Site | Google Scholar
  52. F. R. Homaidan, I. Chakroun, and M. E. El-Sabban, “Regulation of nuclear factor-κB in intestinal epithelial cells in a cell model of inflammation,” Mediators of Inflammation, vol. 12, no. 5, pp. 277–283, 2003. View at: Publisher Site | Google Scholar
  53. F. R. Homaidan, M. E. El-Sabban, I. Chakroun, M. El-Sibai, and G. S. Dbaibo, “IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells,” Mediators of Inflammation, vol. 11, no. 1, pp. 39–45, 2002. View at: Publisher Site | Google Scholar
  54. A. Colell, O. Coll, M. Marí, J. C. Fernández-Checa, and C. García-Ruiz, “Divergent role of ceramide generated by exogenous sphingomyelinases on NF-κB activation and apoptosis in human colon HT-29 cells,” FEBS Letters, vol. 526, no. 1–3, pp. 15–20, 2002. View at: Publisher Site | Google Scholar
  55. A. Sakata, T. Ochiai, H. Shimeno et al., “Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice,” Immunology, vol. 122, no. 1, pp. 54–64, 2007. View at: Publisher Site | Google Scholar
  56. T. Levade and J.-P. Jaffrézou, “Signalling sphingomyelinases: which, where, how and why?” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1438, no. 1, pp. 1–17, 1999. View at: Publisher Site | Google Scholar
  57. D. E. Saslowsky and W. I. Lencer, “Conversion of apical plasma membrane sphingomyelin to ceramide attenuates the intoxication of host cells by cholera toxin,” Cellular Microbiology, vol. 10, no. 1, pp. 67–80, 2008. View at: Publisher Site | Google Scholar
  58. D. Andersson, K. Kotarsky, J. Wu, W. Agace, and R.-D. Duan, “Expression of alkaline sphingomyelinase in yeast cells and anti-inflammatory effects of the expressed enzyme in a rat colitis model,” Digestive Diseases and Sciences, vol. 54, no. 7, pp. 1440–1448, 2009. View at: Publisher Site | Google Scholar
  59. J. J. Miklavcic, K. L. Schnabl, V. C. Mazurak, A. B. R. Thomson, and M. T. Clandinin, “Dietary ganglioside reduces proinflammatory signaling in the intestine,” Journal of Nutrition and Metabolism, vol. 2012, Article ID 280286, 8 pages, 2012. View at: Publisher Site | Google Scholar
  60. K. L. Schnabl, B. Larsen, J. E. Van Aerde et al., “Gangliosides protect bowel in an infant model of necrotizing enterocolitis by suppressing proinflammatory signals,” Journal of Pediatric Gastroenterology and Nutrition, vol. 49, no. 4, pp. 382–392, 2009. View at: Publisher Site | Google Scholar
  61. H. Harizi, J.-B. Corcuff, and N. Gualde, “Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology,” Trends in Molecular Medicine, vol. 14, no. 10, pp. 461–469, 2008. View at: Publisher Site | Google Scholar
  62. M. E. Turini and R. N. DuBois, “Cyclooxygenase-2: a therapeutic target,” Annual Review of Medicine, vol. 53, pp. 35–57, 2002. View at: Publisher Site | Google Scholar
  63. D. C. Montrose, M. Nakanishi, R. C. Murphy et al., “The role of PGE2 in intestinal inflammation and tumorigenesis,” Prostaglandins & Other Lipid Mediators, vol. 116-117, pp. 26–36, 2015. View at: Publisher Site | Google Scholar
  64. B. J. Pettus, C. E. Chalfant, and Y. A. Hannun, “Sphingolipids in inflammation: roles and implications,” Current Molecular Medicine, vol. 4, no. 4, pp. 405–418, 2004. View at: Publisher Site | Google Scholar
  65. L. R. Ballou, C. P. Chao, M. A. Holness, S. C. Barker, and R. Raghow, “Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide,” The Journal of Biological Chemistry, vol. 267, no. 28, pp. 20044–20050, 1992. View at: Google Scholar
  66. A. Huwiler, B. Johansen, A. Skarstad, and J. Pfeilschifter, “Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release,” The FASEB Journal, vol. 15, no. 1, pp. 7–9, 2001. View at: Google Scholar
  67. B. J. Pettus, K. Kitatani, C. E. Chalfant et al., “The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate,” Molecular Pharmacology, vol. 68, no. 2, pp. 330–335, 2005. View at: Publisher Site | Google Scholar
  68. B. J. Pettus, A. Bielawska, S. Spiegel, P. Roddy, Y. A. Hannun, and C. E. Chalfant, “Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release,” The Journal of Biological Chemistry, vol. 278, no. 40, pp. 38206–38213, 2003. View at: Publisher Site | Google Scholar
  69. B. J. Pettus, J. Bielawski, A. M. Porcelli et al., “The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α,” The FASEB Journal, vol. 17, no. 11, pp. 1411–1421, 2003. View at: Publisher Site | Google Scholar
  70. H. Nakamura, T. Hirabayashi, M. Shimizu, and T. Murayama, “Ceramide-1-phosphate activates cytosolic phospholipase A2α directly and by PKC pathway,” Biochemical Pharmacology, vol. 71, no. 6, pp. 850–857, 2006. View at: Publisher Site | Google Scholar
  71. P. Subramanian, R. V. Stahelin, Z. Szulc, A. Bielawska, W. Cho, and C. E. Chalfant, “Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2α and enhances the interaction of the enzyme with phosphatidylcholine,” The Journal of Biological Chemistry, vol. 280, no. 18, pp. 17601–17607, 2005. View at: Publisher Site | Google Scholar
  72. B. J. Pettus, A. Bielawska, P. Subramanian et al., “Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11320–11326, 2004. View at: Publisher Site | Google Scholar
  73. J. Davaille, C. Gallois, A. Habib et al., “Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway,” The Journal of Biological Chemistry, vol. 275, no. 44, pp. 34628–34633, 2000. View at: Publisher Site | Google Scholar
  74. A. M. Johann, A. Weigert, W. Eberhardt et al., “Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression,” The Journal of Immunology, vol. 180, no. 2, pp. 1239–1248, 2008. View at: Publisher Site | Google Scholar
  75. H. K. Sung, J. C. Min, H. L. Chang, and G. K. Sang, “Gα12 specifically regulates COX-2 induction by sphingosine 1-phosphate. Role for JNK-dependent ubiquitination and degradation of IκBα,” The Journal of Biological Chemistry, vol. 282, no. 3, pp. 1938–1947, 2007. View at: Publisher Site | Google Scholar
  76. H. Nakamura and T. Murayama, “Role of sphingolipids in arachidonic acid metabolism,” Journal of Pharmacological Sciences, vol. 124, no. 3, pp. 307–312, 2014. View at: Publisher Site | Google Scholar
  77. J. Wu, Å. Nilsson, B. A. G. Jönsson et al., “Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity,” Biochemical Journal, vol. 394, no. 1, pp. 299–308, 2006. View at: Publisher Site | Google Scholar
  78. N. A. Molodecky, I. S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” Gastroenterology, vol. 142, no. 1, pp. 46.e42–54.e42, 2012. View at: Publisher Site | Google Scholar
  79. O. H. Nielsen and M. A. Ainsworth, “Tumor necrosis factor inhibitors for inflammatory bowel disease,” The New England Journal of Medicine, vol. 369, no. 8, pp. 754–762, 2013. View at: Publisher Site | Google Scholar
  80. W. J. Sandborn, B. G. Feagan, C. Marano et al., “Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, vol. 146, no. 1, pp. 85–95, 2014. View at: Publisher Site | Google Scholar
  81. W. J. Sandborn, G. van Assche, W. Reinisch et al., “Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, vol. 142, no. 2, pp. 257.e3–265.e3, 2012. View at: Publisher Site | Google Scholar
  82. M. L. Høivik, B. Moum, I. C. Solberg, M. Henriksen, M. Cvancarova, and T. Bernklev, “Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN study,” Gut, vol. 62, no. 3, pp. 368–375, 2013. View at: Publisher Site | Google Scholar
  83. A. N. Margioris, “Fatty acids and postprandial inflammation,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 2, pp. 129–137, 2009. View at: Publisher Site | Google Scholar
  84. A. Laegreid, A.-B. Kolsto Otnaess, and J. Fuglesang, “Human and bovine milk: comparison of ganglioside composition and enterotoxin-inhibitory activity,” Pediatric Research, vol. 20, no. 5, pp. 416–421, 1986. View at: Publisher Site | Google Scholar
  85. R. Rueda, J. Maldonado, E. Narbona, and A. Gil, “Neonatal dietary gangliosides,” Early Human Development, vol. 53, pp. S135–S147, 1998. View at: Publisher Site | Google Scholar
  86. J. Xu, V. Anderson, and S. M. Schwarz, “Dietary GD3 ganglioside reduces the incidence and severity of necrotizing enterocolitis by sustaining regulatory immune responses,” Journal of Pediatric Gastroenterology and Nutrition, vol. 57, no. 5, pp. 550–556, 2013. View at: Publisher Site | Google Scholar
  87. H. Furuya, S. Ohkawara, K. Nagashima, N. Asanuma, and T. Hino, “Dietary sphingomyelin alleviates experimental inflammatory bowel disease in mice,” International Journal for Vitamin and Nutrition Research, vol. 78, no. 1, pp. 41–48, 2008. View at: Publisher Site | Google Scholar
  88. J. C. Mazzei, H. Zhou, B. P. Brayfield, R. Hontecillas, J. Bassaganya-Riera, and E. M. Schmelz, “Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of peroxisome proliferator-activated receptor γ expression,” Journal of Nutritional Biochemistry, vol. 22, no. 12, pp. 1160–1171, 2011. View at: Publisher Site | Google Scholar
  89. K. Leucht, A. Fischbeck, M. Caj et al., “Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells,” Molecular Nutrition and Food Research, vol. 58, no. 4, pp. 782–798, 2014. View at: Publisher Site | Google Scholar
  90. Y. Cheng, L. Ohlsson, and R.-D. Duan, “Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice,” British Journal of Nutrition, vol. 91, no. 5, pp. 715–723, 2004. View at: Publisher Site | Google Scholar
  91. I. Soo, K. L. Madsen, Q. Tejpar et al., “VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation,” Canadian Journal of Gastroenterology, vol. 22, no. 3, pp. 237–242, 2008. View at: Google Scholar
  92. M. López-Lázaro, “Distribution and biological activities of the flavonoid luteolin,” Mini Reviews in Medicinal Chemistry, vol. 9, no. 1, pp. 31–59, 2009. View at: Publisher Site | Google Scholar
  93. L. Abdel Hadi, C. Di Vito, G. Marfia et al., “Sphingosine kinase 2 and ceramide transport as key targets of the natural flavonoid luteolin to induce apoptosis in colon cancer cells,” PLoS ONE, vol. 10, no. 11, Article ID e0143384, 2015. View at: Publisher Site | Google Scholar
  94. M. Matloubian, C. G. Lo, G. Cinamon et al., “Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1,” Nature, vol. 427, no. 6972, pp. 355–360, 2004. View at: Publisher Site | Google Scholar
  95. T. Mizushima, T. Ito, D. Kishi et al., “Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis,” Inflammatory Bowel Diseases, vol. 10, no. 3, pp. 182–192, 2004. View at: Publisher Site | Google Scholar
  96. C. Daniel, N. Sartory, N. Zahn, G. Geisslinger, H. H. Radeke, and J. M. Stein, “FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells,” Journal of Immunology, vol. 178, no. 4, pp. 2458–2468, 2007. View at: Publisher Site | Google Scholar
  97. M. G. Sanna, J. Liao, E. Jo et al., “Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate,” Journal of Biological Chemistry, vol. 279, no. 14, pp. 13839–13848, 2004. View at: Publisher Site | Google Scholar
  98. H. Shimizu, M. Takahashi, T. Kaneko et al., “KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts,” Circulation, vol. 111, no. 2, pp. 222–229, 2005. View at: Publisher Site | Google Scholar
  99. J. Song, C. Matsuda, Y. Kai et al., “A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 1, pp. 276–283, 2008. View at: Publisher Site | Google Scholar
  100. Y. Sanada, T. Mizushima, Y. Kai et al., “Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis,” PLoS ONE, vol. 6, no. 9, Article ID e23933, 2011. View at: Publisher Site | Google Scholar
  101. J. Dong, H. Wang, J. Zhao et al., “SEW2871 protects from experimental colitis through reduced epithelial cell apoptosis and improved barrier function in interleukin-10 gene-deficient mice,” Immunologic Research, vol. 61, no. 3, pp. 303–311, 2015. View at: Publisher Site | Google Scholar
  102. P. J. Gonzalez-Cabrera, S. Brown, S. M. Studer, and H. Rosen, “S1P signaling: new therapies and opportunities,” F1000Prime Reports, vol. 6, article 109, 2014. View at: Publisher Site | Google Scholar
  103. L. W. Maines, L. R. Fitzpatrick, C. L. Green, Y. Zhuang, and C. D. Smith, “Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease,” Inflammopharmacology, vol. 18, no. 2, pp. 73–85, 2010. View at: Publisher Site | Google Scholar
  104. L. W. Maines, L. R. Fitzpatrick, K. J. French et al., “Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase,” Digestive Diseases and Sciences, vol. 53, no. 4, pp. 997–1012, 2008. View at: Publisher Site | Google Scholar
  105. X.-F. Wu, X.-X. Wu, W.-J. Guo et al., “Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes,” Toxicology and Applied Pharmacology, vol. 263, no. 3, pp. 296–302, 2012. View at: Publisher Site | Google Scholar

Copyright © 2016 Loubna Abdel Hadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.